<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343163">
  <stage>Registered</stage>
  <submitdate>6/07/2011</submitdate>
  <approvaldate>8/07/2011</approvaldate>
  <actrnumber>ACTRN12611000705987</actrnumber>
  <trial_identification>
    <studytitle>Can less be better? Is it possible to improve constipation symptom control in palliative care patients when the underlying causes of bowel dysfunction are objectively assessed?</studytitle>
    <scientifictitle>A multi-site cluster randomised controlled trial comparing the severity of constipation symptoms experienced by palliative care patients receiving usual care compared to those diagnosed and managed according to the underlying pathophysiology.</scientifictitle>
    <utrn>U1111-1122-6883</utrn>
    <trialacronym>Can Less Be Better Study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Constipation</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants randomised to the intervention arm will undertake the comprehensive assessment at the commencement of the study, allowing allocation to one of three diagnostic sub-categories. These include 1) Slow transit alone; 2) Slow transit and delayed outlet; and 3) Delayed outlet alone. For each category, general and targeted interventions appropriate to the patient population will be trialed. These include general interventions such as hydration, exercise, toileting position and prescribing a toileting routine. Specific interventions for slow transit for example, will include the use of stimulant laxatives and for outlet delay will involve the prescription of a regular suppository. 

Participants randomised to the control groups will receive laxatives as recommended in the management of constipation by Australian Therapeutic Guidelines.

The Australian-modified Karnofsky Performance Status (AKPS) will be used to assess eligibility. All patients will undergo the Bowel Symptom Questionnaire (BSQ), Patient Assessment of Constipation Symptoms (PAC-SYM) and the Patient Assessment of Constipation Quality of Life (PAC-QOL) on entry into the study regardless of which group they are allocated to. Family distress questionnaire will also be collected on entry into the study.
Clinical data and diagnostic interventions will also be collected with the investigations including measurement of colon transit times, and assessment of the structures of defecation with balloon expulsion and anal manometry. The investigations will require one week to complete.
For those randomised to the intervention arm, participants will undertake the diagnostic interventions prior to commencing the 14 day study period. Whilst this is underway, participants constipation will be managed as per usual care, and they will be asked to complete a 7 day bowel diary.
For those randomised to the usual practice arm, participants will be invited to participate in a sub-study where they undergo the same diagnostic interventions as the intervention group.
All participants will be assessed at day 14 with the PAC-SYM and the PAC-QOL, and family distress questionnaire. Whilst on the study, all people will be asked to fill out a daily diary which includes a bowel chart that records actual bowel movement and type, abdominal pain or bloating, and laxatives used. Finally, the ROME III Questionnaire to allow quantification of the numbers of people who come to palliative care services with a past history of functional constipation, and will allow an assessment as to whether this impacts the severity of symptoms they now experience. People will be stratified according to whether they had a feeling of complete evacuation less or more than 2 days per 7 days. Such stratification will allow a comparison of this with the PAC-SYM and PAC-QOL. The Symptom Assessment Scale (SAS) and any adverse effects will be collected as part of this diary. Participants will also receive a telephone call on day 7 to collect data on diary compliance, side effects and medical care. </interventions>
    <comparator>The control treatment will be laxatives as recommended in the management of constipation by Australian Therapeutic Guidelines.: Palliative Care (2010) as detailed below:

Self-reports of passing soft stool: 
docusate+sennoside B 100+16 mg (=2 tablets) orally, once or twice daily.
If second agent needed
bisacodyl 10 mg (=2 tablets) orally, at night, increasing to a maximum of 10 mg twice daily.
+/- bisacodyl 10 mg suppository rectally.

Self-reports of passing hard stool: 
docusate+sennoside B 100+16 mg (=2 tablets) orally, once or twice daily
OR
macrogol 3350 1 to 3 sachets in 500 ml of water orally, taken over 2 hours daily.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare whether the constipation severity of participants allocated to a mechanistic approach to the assessment and treatment of constipation within different sub categories have better patient outcomes than people palliated using standard current clinical care using the Patient Assessment of Constipation Symptoms (PAC-SYM).</outcome>
      <timepoint>Day 15</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To trial an approach to constipation that enables the underlying problems (slow transit of colonic contents, delayed outlet of colonic contents and their overlap), to be quantified in palliative care patients using well-tolerated and validated diagnostic methods. These are Colon Transit Test, Digital Rectal Examination, Anal Manometry, and Balloon Expulsion Test. For those in the usual practice arm and who agree to participate int he sub-study, the same tests will be performed.</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the number and type of laxatives used in each arm. This will be collected by a participant diary that is completed daily throughout the study period for both intervention and control arm.</outcome>
      <timepoint>Daily throughout the 14 day study period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To measure whether changes in quality of life occur both between the study groups and over the time the groups are on the study. A comparison between baseline and exit scores on the PAC-QOL will be made for each participant.</outcome>
      <timepoint>Baseline, day 15, follow-up week 2 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether there are differences in the frequency with which bowel actions are reported between the two groups. This will be collected by a participant diary that is completed daily throughout the study period.</outcome>
      <timepoint>Daily throughout the 14 day study period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether there is a difference between the number of people who achieve a sense of complete evacuation more than two times in each seven days period between the two groups. This will be collected by a participant diary that is completed daily throughout the study period.</outcome>
      <timepoint>Daily throughout the 14 day study period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To retrospectively consider the management of constipation when usual care is delivered and a person has been allocated to a constipation diagnostic subgroup. Participants in the Intervention Units will complete a 7-day Participant diary whilst undertaking the diagnostic tests. Additionally, participants from the usual practice units, who agree to participate in the sub-study will be allocated to a diagnostic subgroup on completion of the sub-study.</outcome>
      <timepoint>Day 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess whether changes in the SAS scores occur over the time of the study</outcome>
      <timepoint>Daily throughout the 14 day study period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the relationship between performance status using the AKPS and constipation. The Australian-modified Karnofsky Performance Status (AKPS) will be compared to the Patient Assessment of Constipation Symptoms (PAC-SYM).</outcome>
      <timepoint>Baseline, day 7, day 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the effect of opioid use on constipation over the 14 day intervention period using a patient diary.</outcome>
      <timepoint>Day 15</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the relationship between anti-cholinergic load and constipation. This will be collected by a participant diary that is completed daily throughout the study period. The anticholinerigc load will be calculated based on  medications with an anticholinergic load the person is receiving.</outcome>
      <timepoint>Baseline and daily diary for 14 days.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To undertake an economic analysis of the management of constipation in people with a life-limiting illness. The economic analysis will estimate incremental resource use, costs, participant effects and the net clinical benefits of an algorithmic approach versus standard current clinical care in the assessment and treatment of constipation from patient level data collected over 28 days of follow up.</outcome>
      <timepoint>Follow-up weeks 2 and 4</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the impact of constipation on family/carer's distress. 
Family distress will be assessed using the Caregiver Quality of Life Index - Cancer (CQOLC) which includes questions covering the psychological distress domain whilst also providing a broader measure of carer quality of life.</outcome>
      <timepoint>Baseline, day 7, day 15, follow-up weeks 2 and 4</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Life-limiting disease 
Aged 18 years or older
Regular use of laxatives
Already receiving one or more laxatives for at least 48 hours, as suggested in the Australian Palliative Care Therapeutic Guidelines 
Sufficient proficiency in English to provide consent, complete the study questionnaires and telephone interviews
Willing and able to undertake diagnostic interventions 
Able to give fully informed written consent </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Short-term constipation due to problems such hypercalcaemia or vinca alkylating agents occurring within one month of study 
History of bowel obstruction or at high risk of bowel obstruction (peritoneal disease)
History of bowel surgery 
Local conditions of the peri-anal area and rectum that would contribute to pain on defecation, require specialist interventions and therefore preclude the necessary investigatons to continue on this study including faecal impaction, anal fissure, haemorrhoids, anal prolapse or rectocele &gt;2cm in size 
Thrombocytopenia of &lt;50,000 platelets per microlitre precluding rectal interventions 
Allergy to latex 
Participants who have participated in a clinical study of a new laxative within one month prior to study entry
Women who are pregnant. Patients at risk of pregnancy must have appropriate and effective contraceptive in place (or appropriate advice from their doctor regarding appropriate birth control)
Any other condition that would interfere with study procedures or assessments in the opinion of the investigators </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All people with a life-limiting illness and a diagnosis of constipation should be referred to the study. The clinician will undertake the initial discussion regarding participation. Obtaining consent for this study will be a process of information exchange between the study staff, the potential participant and any other person the potential participant believes should be included in the discussion.   The participant information sheet will be used as a basis for the discussion, which will cover all procedures, benefits, burdens and side effects expected or possible during the study.  The participant will be given opportunity (in time and physical capacity) to consider the study and formulate questions.  Any questions will be addressed and answered fully.
Allocation is not concealed.</concealment>
    <sequence>The unit of randomisation for this study will be by participant. Individuals will be randomised to either the usual practice arm or the intervention are in a 1:1 ratio. Randomisation tables are developed for each site using random number tables, generated at an independent centre (central registry).
The study nurse will be aware of treatment allocation and will assess participants after 14 days of treatment. The statistician will be blinded to participantâ€™s sub-category and intervention.

Participants at each site will be allocated a series of identifying numbers. A two digit study number, a two digit site number, and a sequential three digit screening number will be allocated on referral to the study. This ID number will be used for all subsequent study documentation for that participant. </sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>The unit of randomisation will be at the participant level.</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>6/08/2011</anticipatedstartdate>
    <actualstartdate>29/07/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/12/2014</actualenddate>
    <samplesize>210</samplesize>
    <actualsamplesize>91</actualsamplesize>
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Calvary Mater Newcastle - Waratah</hospital>
    <hospital>Braeside Hospital - Prairiewood</hospital>
    <hospital>Sacred Heart Hospice - Darlinghurst</hospital>
    <hospital>St Vincent's Hospital (Melbourne) Ltd - Fitzroy</hospital>
    <hospital>Greenwich Hospital - Greenwich</hospital>
    <hospital>Nepean Hospital - Kingswood</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <postcode>2310</postcode>
    <postcode>2164</postcode>
    <postcode>2010</postcode>
    <postcode>3002</postcode>
    <postcode>2176 - Prairiewood</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>2065 - Greenwich</postcode>
    <postcode>2747 - Kingswood</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>2170 - Liverpool</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Flinders University</primarysponsorname>
    <primarysponsoraddress>Palliative Care Clinical Studies Collaborative
700 Goodwood Road
Daw Park, SA 5041</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Natinal Health and Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra
ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Constipation is a common, distressing and serious symptom, affecting between 50-90% of people referred to specialist palliative care services, with 40-70% of people failing to achieve adequate symptom control. The number of people failing to achieve satisfactory symptom relief is not acceptable as inadequate symptom relief is responsible for adding to individual and societal burdens. In palliative care, decisions regarding the prescription of laxatives are based predominantly on clinical experience and institutional approaches. Many of these do not consider the pathophysiological basis that underlies the symptom of constipation. This approach is very dissimilar to that adopted by gastroenterologists in the treatment of non-palliative care patients. The most striking difference is the limited information to categorise the palliative population into the groupings that gastroenterologists would routinely use, thereby limiting the ability to tailor interventions to improve symptom control. This study will aim 
1). To develop an approach to constipation that enables the underlying problems (slow transit of colonic contents, delayed outlet of colonic contents or an overlap of these problems), to be quantified in palliative care patients using well-tolerated and validated diagnostic methods;
2). To compare whether the constipation severity of those patients randomly allocated to a mechanistic approach to the assessment and treatment of constipation within different sub categories have better patient outcomes than people palliated using standard current clinical care.</summary>
    <trialwebsite>None</trialwebsite>
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Ressearch Ethics Committee</ethicname>
      <ethicaddress>Locked Bag 7
Hunter regional Mail Centre
Warabrook NSW 2310</ethicaddress>
      <ethicapprovaldate>24/06/2011</ethicapprovaldate>
      <hrec>11/03/16/4.01</hrec>
      <ethicsubmitdate>28/02/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre Ethics Committee</ethicname>
      <ethicaddress>St Andrews Place
East Melbourne
Victoria 8006</ethicaddress>
      <ethicapprovaldate>11/01/2012</ethicapprovaldate>
      <hrec>HREC/11/PMCC/24</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Katherine Clark</name>
      <address>Calvary Mater Newcastle
Locked Bag 7
Hunter regional Mail Centre
Warabrook NSW 2310</address>
      <phone>+61 2 4921 1953</phone>
      <fax>+61 2 4921 1952</fax>
      <email>naomi.byfielt@calvarymater.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Naomi Byfieldt</name>
      <address>Calvary Mater Newcastle
Locked Bag 7
Hunter regional Mail Centre
Warabrook NSW 2310</address>
      <phone>+61 2 4921 1953</phone>
      <fax>+61 2 4921 1952</fax>
      <email>naomi.byfielt@calvarymater.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Belinda Fazekas</name>
      <address>Flinders University
Palliative Care Clinical Studies Collaborative
700 Goodwood Road
Daw Park
SA 5041</address>
      <phone>+61 8 8275 1396</phone>
      <fax>+61 8 8374 0350</fax>
      <email>belinda.fazekas@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Katherine Clark</name>
      <address>Calvary Mater Newcastle Locked Bag 7 Hunter regional Mail Centre Warabrook NSW 2310  </address>
      <phone>+61 2 4921 1953</phone>
      <fax>+61 2 4921 1952</fax>
      <email>Katherine.Clark@calvarymater.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>